Our data are good enough.

M. Walberg

DOI: https://doi.org/10.4045/tidsskr.11.0680

2011-08-09

Abstract:

What problem does this paper attempt to address?

Botulinum toxin A for the treatment of strabismus in children with neurological impairment

Betul Tugcu,Bilge Araz-Ersan,Seyhan B Özkan

DOI: https://doi.org/10.5935/0004-2749.2021-0401

2023-03-24

Abstract:Purposes: To assess the efficacy of botulinum toxin A injection in the treatment of strabismus in patients with neurological impairment and evaluate the factors associated with treatment success. Methods: The study included 50 patients with strabismus and neurological impairment. In all children, botulinum toxin injection was performed into the appropriate extraocular muscle. The relationship between demographic features, clinical characteristics, and treatment success were analyzed. Results: In the study group, 34 patients had esotropia, and 16 patients had exotropia. As neurological problems, 36 patients had cerebral palsy, and 14 had hydrocephalus. The average follow-up period was 15.3 ± 7.3 months. The mean number of injections was 1.4 ± 0.6. The mean angle of deviation was 42.5 ± 13.2 PD before the treatment, which decreased to 12.8 ± 11.9 PD after the treatment. Successful motor alignment (orthotropia within 10 PD) was achieved in 60% of the patients. Binary logistic regression analysis revealed that esotropic misalignment and shorter duration of strabismus was significantly associated with treatment success in the study group. Patients with esotropia and lower angles of misalignment were more likely to be treated with a single injection. Conclusion: The use of botulinum toxin A for the treatment of strabismus in children with neurological impairment is a good alternative to conventional surgical therapy with a lower risk of overcorrection. The treatment outcome is better in esodeviations and shorter duration of strabismus, implying an advantage of early treatment.
Botulinum toxin for the treatment of strabismus

Angeles R Bort-Martí,Fiona J Rowe,Laura Ruiz Sifre,Sueko M Ng,Sylvia Bort-Martí,Vicente Ruiz Garcia

DOI: https://doi.org/10.1002/14651858.CD006499.pub5

2023-03-14

Abstract:Background: The use of botulinum toxin as an investigative and treatment modality for strabismus is well reported in the medical literature. However, it is unclear how effective it is in comparison with other treatment options for strabismus. Objectives: The primary objective was to examine the efficacy of botulinum toxin therapy in the treatment of strabismus compared with alternative conservative or surgical treatment options. This review sought to ascertain those types of strabismus that particularly benefit from the use of botulinum toxin as a treatment option (such as small angle strabismus or strabismus with binocular potential, i.e. the potential to use both eyes together as a pair). The secondary objectives were to investigate the dose effect and complication rates associated with botulinum toxin. Search methods: We searched CENTRAL, MEDLINE, Embase, LILACS and three trials registers on 6 July 2022, together with reference checking to identify additional studies. We did not use any date or language restrictions in the electronic searches for trials. Selection criteria: We planned to include randomized controlled trials (RCTs) comparing botulinum toxin with strabismus surgery, botulinum toxin alternatives (i.e. bupivacaine) and conservative therapy such as orthoptic exercises, prisms, or lens therapy for people of any age with strabismus. All relevant RCTs identified in this update compared botulinum toxin with strabismus surgery. Data collection and analysis: We used standard methods expected by Cochrane and assessed the certainty of the body of evidence using GRADE. Main results: We included four RCTs with 242 participants that enrolled adults with esotropia or exotropia, children with acquired esotropia, and children with infantile esotropia. The follow-up period ranged from six to 36 months. Two studies were conducted in Spain, and one each in Canada and South Africa. We judged the included studies to have a mixture of low, unclear and high risk of bias. We did not consider any of the included studies to be at low risk of bias for all domains. All four studies reported the proportion of participants who improved or corrected strabismus, defined as ≤ 10 prism diopters (PD) at six months (two studies) or ≤ 8 PD at one year (two studies). Low-certainty evidence suggested that participants treated with the surgery may be more likely to improve or correct strabismus compared with those who treated with botulinum toxin (risk ratio (RR) 0.72, 95% confidence interval (CI) 0.53 to 0.99; I² = 50%; 4 studies, 242 participants; low-certainty evidence). One study, which enrolled 110 children with infantile esotropia, suggested that surgery may reduce the incidence of additional surgical intervention required, but the evidence was very uncertain (RR 3.05, 95% CI 1.34 to 6.91; 1 study, 101 participants; very low-certainty evidence). Two studies conducted in Spain compared botulinum toxin with surgery in children who required retreatment for acquired or infantile esotropia. These two studies provided low-certainty evidence that botulinum toxin may have little to no effect on achieving sensory fusion (RR 0.88, 95% CI 0.63 to 1.23; I² = 0%; 2 studies, 102 participants) and stereopsis (RR 0.86, 95% CI 0.59 to 1.25; I² = 0%; 2 studies, 102 participants) compared with surgery. Three studies reported non-serious adverse events. Partial transient ptosis (range 16.7% to 37.0%) and transient vertical deviation (range 5.6% to 18.5%) were observed among participants treated with botulinum toxin in three studies. In one study, 44.7% participants in the surgery group experienced discomfort. No studies reported serious adverse events or postintervention quality of life. Authors' conclusions: It remains unclear whether botulinum toxin may be an alternative to strabismus surgery as an independent treatment modality among certain types of strabismus because we found only low and very low-certainty evidence in this review update. Low-certainty evidence suggests that strabismus surgery may be preferable to botulinum toxin injection to improve or correct strabismus when types of strabismus and different age groups are combined. We found low-certainty evidence suggesting botulinum toxin may have little to no effect on achievement of binocular single vision compared with surgery in children with acquired or infantile esotropia. We did not find sufficient evidence to draw any meaningful conclusions with respect to need for additional surgery, quality of life, and serious adverse events. We identified three ongoing trials comparing botulinum toxin with conventional surgeries in the varying types of strabismus, whose results will provide relevant evidence for our stated objectives. Future trials should be rigorously designed, and investigators should analyze outcome data appropriately and report adequate information to provide evidence of high certainty. Quality of life and cost-effectiveness should be examined in addition to clinical and safety outcomes.
Factors Affecting the Efficacy of Botulinum Toxin Injection in the Treatment of Infantile and Partially Accommodative Esotropia

Motazz A Alarfaj,Waleed K Alsarhani,Saleh H Alrashed,Faris A Alarfaj,Khabir Ahmad,Abdulaziz Awad,Gorka Sesma

DOI: https://doi.org/10.4103/meajo.meajo_39_23

2023-05-25

Abstract:Purpose: We aimed to investigate the effect of botulinum toxin (BT) injection on the treatment of infantile and partially accommodative esotropia (PAET). Methods: This retrospective cohort study included patients who received BT injections for infantile and PAET between January 2015 and December 2018. Treatment was considered successful if orthotropia, consecutive exotropia, or esotropia within 10 prism diopters (PD) was achieved. Results: The overall success rate was 47.4%, with a mean follow-up period of 27.8 months in 403 children. BT treatment was considered successful in 37.1% of cases of infantile esotropia and 53.1% of cases of partially accommodative esotropia. The average deviation angle before starting treatment was 35.5 ± 13.9 PD. Side effects 1 week after BT injections included transient overcorrection (63.8%) and transient ptosis (41.7%). There were no significant differences in the success rates between the different doses of BT (P = 0.69). The angle of deviation at presentation was significantly associated with the success rate of BT injection (failed group, mean: 38.1 ± 15.3 PD vs. success group, mean: 32.6 ± 11.6 PD; P < 0.001). Other factors associated with higher success rates were overcorrection at 1 week and PAET, while multivariate logistic regression analysis showed that a smaller angle of deviation and overcorrection (1 week after injection) were associated with a higher success rate. Conclusion: A smaller angle of deviation and transient overcorrection were associated with a higher success rate, and no significant difference was observed in the success rates of different BT doses.
Comparison of the Efficiency of the Botulinum Toxin for the Treatment of Esotropia in Children with and without Neurological Disease and/or Prematurity

Mehmet Serhat Mangan,Emel Basar

DOI: https://doi.org/10.1080/2576117X.2020.1826288

Abstract:Objective: To compare the effect of botulinum toxin injection for the management of esotropia in patients with and without neurological disease and/or prematurity. Methods: A single-center, retrospective, nonrandomized controlled study was performed on botulinum toxin in 87 children divided into two groups: study group of esotropia in 56 children with neurological disease and/or prematurity and, control group of 31 healthy children with infantile esotropia. All patients were followed for at least 24 months after injection. Success was defined as motor alignment with 10Δ of orthotropia after single bilateral botulinum injection. Results: Mean age at treatment was similar in both groups (15.5 vs 14.8 months; p = .555). Mean pretreatment deviation was similar in both groups (50.8Δ vs 50Δ; p = .855). The success rate was better in the control group (61.2% vs 51.7%, p = .265) at 24 months after injection, but the change in the mean angle of deviation was not statistically significant between the groups at 12 and 24 months after injection (p = .264 and p = .547, respectively). Multivariate regression analysis showed that pretreatment angle of deviation and presence of retinopathy of prematurity were significant predictors at 12 months after injection (p = .0001 and p = .004, respectively), while pretreatment angle of deviation was found to be a predictor at 24 months after injection (p = .0001). Conclusions: Decreased angle of deviation and absence of retinopathy of prematurity were associated with a better result. There was no difference in motor alignment of esotropia in children with and without neurological disease and/or prematurity. In these patients, botulinum injection may be used as an alternative to surgery.
Comparison of Botulinum Toxin With Surgery for the Treatment of Acute-Onset Comitant Esotropia in Children

Michael J Wan,Iason S Mantagos,Ankoor S Shah,Melanie Kazlas,David G Hunter

DOI: https://doi.org/10.1016/j.ajo.2016.12.024

Abstract:Purpose: To determine whether botulinum toxin is as effective as strabismus surgery in the treatment of acute-onset comitant esotropia in children. Design: Retrospective, nonrandomized, comparative clinical study. Methods: Setting: Tertiary care pediatric hospital. Study population: Forty-nine children with acute-onset comitant esotropia. Intervention: Treatment with either botulinum toxin ("chemodenervation group") or standard incisional strabismus surgery ("surgery group"). Main outcome measure: Success rate at 6 months (total horizontal deviation of 10 prism diopters or less and evidence of binocular single vision). Results: There were 16 patients in the chemodenervation group and 33 patients in the surgery group. The success rate was not significantly different at 6 months (81% vs 61%, P = .20) or at 18 months (67% vs 58%, P = .74). The median angle of deviation and median stereoacuity were not significantly different at 6 or 18 months. The chemodenervation procedure was not inferior to incisional strabismus surgery at 6 months. The duration of general anesthesia (5 vs 71 min, P < .001) and time in the post-anesthesia care unit (37 vs 93 min, P < .001) were significantly shorter in the chemodenervation group. Botulinum toxin injection payment averaged $874 per procedure compared with $2783 for strabismus surgery. Conclusions: Botulinum toxin is at least as effective as surgery in the treatment of acute-onset comitant esotropia at 6 months while reducing the duration of general anesthesia and healthcare costs.
A Comparative Analysis of Surgical Outcomes for Infantile Esotropia With and Without Prior Botulinum Toxin a Injection

Didem Dizdar Yigit,Alev Kockar,Ceren Gurez,Aslı Inal,Birsen Gokyigit

DOI: https://doi.org/10.3928/01913913-20240102-02

IF: 1.33

2024-02-19

Journal of Pediatric Ophthalmology & Strabismus

Abstract:Purpose: To compare the surgical outcomes in patients who had a failed botulinum toxin A injection before surgery versus those who had surgery as primary treatment (primary surgery) for infantile esotropia. Methods: The files of patients who had strabismus surgery in the Strabismus Unit of Beyoglu Eye Training and Research Hospital between January 2012 and March 2022 were reviewed. This study included 104 eyes of 52 patients with infantile esotropia. The angle of deviation before and 1, 3, and 6 months after botulinum toxin A injection or surgery, complications, pattern deviations, family history, abnormal head position, history of prematurity, intensive care unit admission, and consanguineous marriage were noted. A successful outcome was defined as ocular alignment of 10 prism diopters (PD) or less. Results: The study population consisted of 52 patients: 27 (52%) boys and 25 (48%) girls. In the botulinum toxin A group (n = 26), the mean age at admission was 14.0 ± 6.8 months, whereas the mean preoperative near and far angle of deviation were 41.92 ± 12.2 and 41.3 ± 13.0 PD, respectively. The mean age at the time of surgery was 40.6 ± 18.1 months. In the primary surgery group (n = 26), the mean age at admission was 34.0 ± 15.9 months. The mean preoperative near and far angle of deviation were 37.3 ± 8.0 and 35.3 ± 10.5 PD, respec tively. The mean age at the time of surgery was 48.1 ± 18.5 months. The success rates 6 months after treatment in the botulinum toxin A group and the primary surgery group were 76.9% and 88.5% in near ( P > .05) and 80.8% and 88.5% in far ( P > .05), respectively. Three patients had transient ptosis and one had consecutive exotropia after botulinum toxin A injection. Conclusions: In infantile esotropia treatment, strabismus surgery after failed botulinum toxin A injection compared to primary surgery has statistically comparable surgical success rates. [ J Pediatr Ophthalmol Strabismus . 20XX;X(X):XXX–XXX.]

pediatrics,ophthalmology
The role of botulinum toxin in decompensated strabismus

Shveta Bansal,Javeed Khan,Ian B Marsh

DOI: https://doi.org/10.1080/09273970802292693

Strabismus

Abstract:Background: The surgical management of decompensated strabismus is well described. Conservative treatment may employ the use of lenses and prisms. However, the use of botulinum toxin in decompensated squint is poorly documented. In these patients, with the potential for fusion, botulinum toxin may serve to stabilize the ocular alignment by bringing the images within the fusion range. Purpose: The aim of this study was to assess the role of botulinum toxin in the treatment of decompensated squints. Methods: A retrospective case series involving 92 patients with decompensated squints between December 1990 and July 2005. Botulinum toxin was injected into the lateral rectus in 45 cases and into the medial rectus in 47. This was performed under local anesthesia in 74 cases, the remainder with ketamine anesthesia. Patients were assessed preoperatively at 2 weeks, 4 months, and a minimum of 12 months postoperatively. We defined successful treatment where the resultant stabilized deviation was less than or equal to 10 prism diopters with resolution of diplopia. Results: In this study, 47 patients had a decompensated microesotropia and 45 had a decompensated exophoria. We found that 27 (29.3%) patients were asymptomatic following injection of botulinum toxin. Fourteen (15.2%) patients were better controlled and did not require further intervention. Subsequent surgery was performed in 45 patients (48.9%). Conclusion: Our results suggest almost half of those patients requiring treatment for decompensated squint benefit from botulinum toxin, without requiring surgical intervention. This approach is less invasive and allows potential for recovery of binocular function.
Efficacy of Botulinum Toxin Injection in Exotropia Treatment

Seham S Al Hemaidi,Gorka Sesma,Khabir Ahmad,Ruba Saleh Alghofaili,Raseel A Awad

DOI: https://doi.org/10.4103/meajo.meajo_269_21

2021-12-31

Abstract:Purpose: Botulinum toxin (Botox) therapy is a well-known option for strabismus management and is often used in managing esotropia. Exotropia is also a common type of strabismus; however, the effectiveness of Botox in improving exotropia is still ambiguous. In this study, we report our experience in using Botox to manage the various types of exotropia. Methods: A retrospective cohort study was conducted at King Khaled Eye Specialist Hospital Riyadh, Saudi Arabia. Medical records of patients with exotropia who received Botox from 2014 to March 2020 were reviewed. The main success indicator was a remaining angle of less than 10 prism diopters (PD). Results: A total of 97 cases were reviewed, with 57 (58.8%) males and 40 (41.2%) females. The age ranged from 2 months to 40 years. The most prevalent diagnosis was sensory exotropia. Overall, 28 patients (28.9 %) and 49 patients (50.5%) achieved an angle of deviation within 10 PD and within 20 PD, respectively. Female patients had a better response to Botox than males, with 32.5% of them achieving an angle of deviation within 10 PD and 60% achieving an angle of deviation within 20 PD. We found that the change in the angle of deviation increased as the Botox dose was increased. Conclusion: Botox represents a possible safe alternative to surgery in the management of some exotropia types. The success rate differs by type, with basic exotropia scoring the highest. The presence of poor vision and amblyopia leads to a significantly lower success rate.
Long-Term Effects of Botulinum Toxin A for Horizontal Concomitant Strabismus in Chinese Children

Jingjing Jiang,Huaxin Zuo,Siyuan Li,Di Cao,Li Li

DOI: https://doi.org/10.1080/08820538.2023.2181666

Abstract:Introduction: For childhood strabismus, early surgical intervention improves both motor and sensory outcomes. Botulinum toxin type A (BTX-A) injection is an alternative to incisional surgery that is fast, less invasive, and preserves a more normal biomechanical construct. This study was undertaken to assess the safety and effectiveness of BTX-A for horizontal concomitant strabismus in children in our institution. Patients and methods: Records of all children less than age 18 years with follow-up at least 12 months who were treated with BTX-A for horizontal concomitant strabismus at Beijing Children's Hospital between December 2014 and February 2021 were reviewed retrospectively. Bilateral injections of BTX-A (Henli, 1.25 IU to 5 IU/0.1 ml) were made into the medial or lateral rectus muscles according to the angle of deviation. Reinjection was permitted if the initial alignment was not satisfactory within 1 to 6 months post-injection. Motor success was defined as a final misalignment ≤10 PD. Sensory success was defined as the presence of any evidence of sensory fusion, distance stereopsis, or near stereopsis at the last visit. Results: Seventy-one patients were included. Fifty-two had esotropia, and 19 had exotropia. There was a significant decrease in the angle of deviation in all treated patients. The overall motor success rate was 60.6%. The motor success rate was highest in children with esotropia <50 PD (81.5%). Motor success was better for children with partially accommodative esotropia and acquired non-accommodative esotropia (80%, 83.3%, respectively) than for children with infantile esotropia (47.4%). Compared with the esotropia group, the fusion was significantly higher in the exotropia group (p = .007), and the proportion of patients with stereoacuity of better than 100 sec arc was higher also in the exotropia group (71.4%, p = .007), evidence of sensory outcomes were significantly better in the exotropia group. Complications were few. Twenty patients (28.2%) developed transient ptosis after injections; transient vertical deviations were seen in 3 patients (4.2%); and subconjunctival hemorrhage was seen in 5 patients (7%). Conclusions: BTX-A appears to be an effective treatment for the management of horizontal strabismus with motor outcomes best in children with acquired smaller-angle esodeviations. Children with exodeviations had better sensory outcomes in this cohort. A randomized controlled study comparing incisional surgery to BTX-A will be important for guiding future treatment decisions.
Binocular Visual Rehabilitation in Paralytic Strabismus by Botulinum A Toxin Chemodenervation

Myungjin Kim,Helen Lew

DOI: https://doi.org/10.3341/kjo.2021.0054

Abstract:Purpose: To investigate the effect of botulinum A toxin (BTXA) chemodenervation in paralytic strabismus patients without surgical correction. Methods: A retrospective chart review of 51 patients who were diagnosed as paralytic strabismus and underwent BTXA chemodenervation was performed. The patients were divided into four groups according to the cause of paralytic strabismus of vasculopathy, neoplasm, trauma, and idiopathic. They were also divided into two groups of early and late treatment according to the initiation time of BTXA chemodenervation after the onset of strabismus (3 months), and of the initial strabismus type of exotropia and esotropia. We investigated the changes of angle of deviation and diplopia after BTXA chemodenervation. Results: The average deviation of angles decreased by 25.2 prism diopter (PD) (35.1 to 9.9 PD) in total patients, and the overall success rate was 64.7% (33 by 51), and the there was no statistically significant difference in success rate between each group divided by the cause of paralytic strabismus. According to the treatment timing, the deviation of the angle decreased by 28.0 PD (36.8 to 8.8 PD) in the early treatment group, and 21.3 PD (33.5 to 12.2 PD) in late treatment group at the time of the last postinjective follow-up. According to the initial strabismus type, the average angle of deviation decreased by 20.3 PD (35.6 to 15.3 PD) in exotropia group by cranial nerve 3 palsy, and 24.4 PD (32.5 to 8.1 PD) in esotropia by cranial nerve 6 palsy. Conclusions: BTXA chemodenervation reduced the angle of deviation and the number of patients with diplopia regardless of the cause of paralytic strabismus. Early BTXA chemodenervation can be considered as the first treatment of choice in paralytic strabismus, especially in esotropia patients.
Relation between serum magnesium level and migraine attacks.

M. Talebi,D. Savadi-Oskouei,M. Farhoudi,Solmaz Mohammadzade,Seyyedjamal Ghaemmaghamihezaveh,A. Hasani,A. Hamdi

2011-10-01

Neurosciences

Abstract:OBJECTIVE The determination of serum magnesium levels in migraine. METHODS In a case control study performed between January 2007 and December 2007 at Tabriz University of Medical Sciences, Tabriz, Iran, 140 migraine patients were enrolled and their level of serum magnesium was determined and the results were compared with 140 healthy people who did not have any headache, kidney, or gastrointestinal disorders, and no consumption of magnesium complements. RESULTS Migraine patients (22 male, 118 female) with a mean age of 33.82+/-10.31 and 140 healthy people (26 male, 114 female) with a mean age of (34.19+/-9.95) were enrolled. Forty patients had aura and 100 patients did not have aura. The average serum magnesium level in the patient group (26.14+/-4.3) was significantly lower than the control (31.09+/-4.32) group (p=0.000). There was no significant difference between the mean level of serum magnesium in patients with migraine with aura and without aura, however, there was a significant linear relationship between the amount of serum magnesium and the frequency of headache. CONCLUSION Serum magnesium in migraine patients was significantly lower than the normal population and related to the frequency of migraine attacks, supporting the use of magnesium in prevention and treatment of migraine.
Comparison of botulinum toxin with surgery as primary treatment for infantile esotropia

Alejandra G de Alba Campomanes,Gil Binenbaum,Glorialicia Campomanes Eguiarte

DOI: https://doi.org/10.1016/j.jaapos.2009.12.162

Abstract:Purpose: To compare bilateral medial rectus muscle injection of botulinum toxin with surgery as primary treatment for infantile esotropia. Methods: A single-center, prospective, nonrandomized comparative study was undertaken of botulinum toxin versus surgery in children who presented by age 36 months with esotropia onset before 12 months. Successful outcome was defined as ocular alignment within 10Delta of orthotropia after one surgery or 1 to 3 bilateral botulinum injections. Results: Of 442 subjects, 322 received botulinum toxin (1 injection, 49%; 2, 41%; 3, 10%); 120 had surgery. Motor success was achieved in 66% of surgery patients, compared with 45% of botulinum patients (p < 0.001). Among subjects with deviation >30Delta, surgery achieved 69% success versus 36% with botulinum toxin (relative risk, 1.95; 95% CI, 1.53-2.49). At deviations < or = 30Delta, there was no difference (surgery, 60%; botulinum toxin, 59%; relative risk, 1.03; 95% CI, 0.78-1.35). There were no statistically significant differences in mean pretreatment deviation (botulinum toxin, 38.8Delta; surgery, 38.2Delta) or mean follow-up (botulinum toxin, 22.6 months; surgery, 20.7). Surgery occurred later than botulinum injection (mean age at treatment, 27.0 vs. 16.7 months; p < 0.001) with greater duration of misalignment (21.0 vs 12.5 months, respectively; p < 0.001), but neither variable influenced outcome in multivariate regression. Conclusions: In this large, nonrandomized prospective cohort, surgery was more successful than botulinum toxin in the treatment of large-angle esotropia. Botulinum toxin appeared most effective for esotropia <30Delta to 35Delta, with a success rate comparable with surgery. Botulinum toxin may be an alternative to surgery in children with small- to moderate-angle infantile esotropia.
Botulinum toxin management of childhood intermittent exotropia

R F Spencer,M G Tucker,R Y Choi,K W McNeer

DOI: https://doi.org/10.1016/s0161-6420(97)30029-3

IF: 14.277

Ophthalmology

Abstract:Objective: Intermittent exotropia is a common form of childhood strabismus that has a late onset and presents a difficult and frustrating management dilemma. Surgical treatments have a high recurrence rate, and multiple surgeries often are required to achieve a desirable motor outcome. This study presents long-term observations on the use of botulinum toxin for the treatment of intermittent exotropia in children. Design: This study is a nonrandomized, case-controlled study of consecutive pediatric patients who had intermittent exotropia. Participants: Thirty-two neurologically normal children ranging from 3 to 144 months in age were diagnosed with intermittent exotropia with a minimum distance deviation of 15 prism diopters (PD). Intervention: Simultaneous bilateral injections of 2.5 units botulinum toxin type A were made into the lateral rectus muscles with the patient receiving nitrous oxide-ethrane inhalation anesthesia. Patients were observed for 12 to 44 months after the initial injection. Main outcome measures: A satisfactory outcome was considered to be stable binocular alignment of the eyes to an orthophoric range of +/-10 PD. Results: Bilateral lateral rectus muscle injections of botulinum toxin were effective in reducing the mean preinjection deviation of -29 PD to an average exotropic angle of -6 PD. Stable orthophoria (+/-10 PD) was achieved in 22 patients (69%). Overall, male patients required significantly fewer injections than did female patients. All patients between 24 and 56 months of age, irrespective of gender, required only a single bilateral injection to achieve a favorable motor outcome. Conclusions: Botulinum toxin is at least as effective as surgical outcomes reported previously for the treatment of intermittent exotropia in children. This treatment method is particularly effective in children between 2 and 4.5 years of age irrespective of the initial strabismic angle and is not associated with any secondary abnormalities.
Structure-release rate correlation in collagen gels containing fluorescent drug analog.

Silvia H De Paoli Lacerda,B. Ingber,N. Rosenzweig

DOI: https://doi.org/10.1016/J.BIOMATERIALS.2005.05.032

IF: 14

2005-12-01

Biomaterials

Abstract:
Botulinum Toxin in the treatment of strabismus. A review of its use and effects

Lionel Kowal,Elaine Wong,Claudia Yahalom

DOI: https://doi.org/10.1080/09638280701568189

2007-01-01

Disability and Rehabilitation

Abstract:Botulinum Toxin as a medical therapy was introduced by Dr Alan Scott more than 20 years ago. The first clinical applications of Botulinum Toxin type A (BT-A) were for the treatment of strabismus and for periocular spasms. Botulinum Toxin type A is often effective in small to moderate angle convergent strabismus (esotropia) of any cause, and may be an alternative to surgery in these cases. Botulinum Toxin type A may have a role in acute or chronic fourth and sixth nerve palsy, childhood strabismus and thyroid eye disease. The use of BT-A for strabismus varies enormously in different cities and countries for no apparent reason. Botulinum Toxin type A may be particularly useful in situations where strabismus surgery is undesirable. This may be in elderly patients unfit for general anaesthesia, when the clinical condition is evolving or unstable, or if surgery has not been successful. Botulinum Toxin type A can give temporary symptomatic relief in many instances of bothersome diplopia irrespective of the cause. Ptosis and acquired vertical deviations are the commonest complications encountered. Vision-threatening complications are rare. Repeated use of BT-A is safe.

rehabilitation
Exploration of Effect and Dosage of Botulinum Toxin Type A for Long-Term Treatment of Idiopathic Blepharospasm

胡兴越,蔡华英,邵宇权

DOI: https://doi.org/10.3969/j.issn.1007-7669.2004.01.011

2004-01-01

Abstract:AIM: To explore the relationship between the efficacy and the dosage of botulinum toxin type A (BTXA) for long-term and repetitive treatment of blepharospasm. METHODS: 178 patients repetitively treated with BTXA were followed up for 7 a. The dosage, effect, effect duration, and adverse reations of 6 sessions were compared among themselves. The severity of blepharospasm was gauged by Cohen scale. SAS software package was administered for statistic analysis. RESULTS: 178,138,112,83,63, and 48 patients were enrolled in the consequently 6 sessions in 7 a. The withdraw rates were 14.0 %(25/178) (P0.05),5.1 %(7/138), 5.4 %(6/112),6 %(5/83) and 6 %(4/63) since the second session. The effective rate of each session was 89.9 %(160/178),97.1 %(134/138),96.4 %(108/112),95 %(79/83),95 %(60/63), and 98 %(47/48), respectively. The average BTXA dosage was about 70 U, and the mean duration of improvement was 15-16 wk. Though the lower effective rate in the first session compared with the second and third sessions, there were no significant differences among other sessions in the effective rate, mean dosage and duration of improvement. The incidence rates of adverse reactions were 36.5 %(65/178),31.9 %(44/138),31.3 %(35/112),31 %(26/83),30 %(19/63) and 29 %(14/48) respectively in each session, and there were no significant differences in statistic analysis. The adverse reactions of focal weakness occurred at 2-3 d after effect emerged and lasted 2-6 wk. The most concerned complications were ptosis, blurred vision and diplopia. The ptosis occurred 10.1 % in the first session, which had statistic difference (P0.05) compared with the second and third sessions (3.6 %-3.6 %). The adverse reaction rate was 30 % on the whole. CONCLUSION: Without increasing dose, the long-term therapeutic effect and duration of improvement can be maintained by repeated topical BTXA injection. The incidence of adverse reactions such as ptosis can be reduced.
Long-term results of botulinum toxin in consecutive and secondary exotropia: outcome in patients initially treated with botulinum toxin

J M Lawson,L Kousoulides,J P Lee

DOI: https://doi.org/10.1016/s1091-8531(98)90052-0

Abstract:Introduction: Long-term ocular alignment can be difficult to achieve in patients with consecutive and secondary (sensory) exotropia, and botulinum neurotoxin A (BTXA) is a recognized alternative to surgery in this group. Patients and methods: We reviewed the results of 44 patients aged 15 to 77 years (mean 31 years) who underwent their first BTXA injections from 1989 to 1990. In 30% of cases the choice of toxin treatment was made by the patient. In the remainder BTXA was recommended by the clinician to assess the risk of postoperative diplopia. Thirty-three patients (75%) were consecutively exotropic and 68% of patients had had previous strabismus surgery. The mean preinjection deviation was 41 delta of exotropia (range 12 to 85 delta exotropia) and the minimum mean angle change after 1 injection was 27 delta (range 0 to 57 delta). The average number of injections was 3 (range 1 to 17). Results: Of the patient group, 59% went on to strabismus surgery, 14% continued to attend for maintenance treatment, and 9% were discharged with a small, stable deviation. The remainder were either followed up elsewhere or failed to reattend. Conclusions: Botulinum toxin appears to be a satisfactory treatment for constant exotropia in patients at risk of postoperative diplopia who have undergone multiple operations but, because more than half the group went on to surgery, surgery as a first therapy may be preferable in uncomplicated cases.
Evaluation of the efficacy of botulinum toxin injection for the treatment of infantile esotropia

Muneeb Alam,Sarah Alshammari,Saif Alobaisi,Shatha Alfreihi

DOI: https://doi.org/10.4103/sjopt.sjopt_36_22

2023-06-26

Abstract:Purpose: The purpose of this study was to investigate the outcomes and complications of botulinum toxin injection (BTX) as the primary treatment of infantile esotropia (IET). Methods: We included patients with IET who underwent BTX from 2015 to 2020. IET was defined as esotropia present before 12 months of age, with no significant refractive error, or limitation of rotations. We defined success as a postoperative angle of 0-10 prism diopters (PD). Results: Sixty-three patients met our inclusion criteria (38 male patients [60.3%]). The mean age was 18 ± 8 months (range: 10-26), onset 6 ± 4 months (range: 2-10), and follow-up of 29 ± 25 months (range: 4-54). Amblyopia was present in 45 patients (71.4%). Number of BTX was, 1 in 42 (66.7%), 2 in 17 (27%), 3 in 4 (4.8%), and 4 in 1 (1.6%). The 1st BTX mean dose was 7 ± 3 international unit (range: 4-10) and a mean duration of 4 ± 1 min (range: 3-5). The mean preoperative angle of deviation was 42.30 ± 13.73 PD. The mean postoperative angle of deviation was 16.07 ± 16.15 PD (P = 0.0001). At the final follow-up, BTX was successful in 32 (51%) (success after 1st BTX 33.3%, 2nd BTX 46.03%, and 3rd BTX 50.79%). Twelve patients (19%) had undergone surgery due to the failure of BTX. Postoperative observations included transient ptosis 29 (49.2%), transient exotropia 36 (57.14%), inferior oblique overaction 13 (20.6%), vertical deviation 8 (12.7%), and persistent ptosis 1 (1.6%). Conclusion: The success rate of BTX for IET was 51%. BTX can be offered as an alternative to surgery to those who cannot undergo prolonged anesthesia or where accurate measurements could not be obtained.
Botulinum Toxin Injection versus Extraocular Muscle Surgery for Acute Acquired Comitant Esotropia

Sirinya Suwannaraj,Chawisa Rojanasaksothron,Yanasiri Methapisittikul,Phanthipha Wongwai,Yosanan Yospaiboon

DOI: https://doi.org/10.2147/OPTH.S401019

2023-01-31

Clinical Ophthalmology

Abstract:Sirinya Suwannaraj, Chawisa Rojanasaksothron, Yanasiri Methapisittikul, Phanthipha Wongwai, Yosanan Yospaiboon KKU Eye Center, Department of Ophthalmology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand Correspondence: Yosanan Yospaiboon, KKU Eye Center, Department of Ophthalmology, Faculty of Medicine, Khon Kaen University, 123 Mitraparb Highway, Khon Kaen, 40002, Thailand, Tel +66-4336-3010, Fax +66-4334-8383, Email Purpose: To compare the success rate of extraocular muscle surgery and botulinum toxin injection for treatment in patients with acute acquired comitant esotropia (AACE). Patients and Methods: This is a retrospective cohort study in which we treated 34 patients of AACE with botulinum toxin compared with 80 patients who had been treated with surgery. The data included angle of deviation in prism diopter (PD) at baseline and one, three, and six months after treatment. The main outcome was the success rate in each treatment group. Results: In the surgery group, mean esodeviation angles at baseline and one, three, and six months after treatment were 50.8 ± 18.3 PD, 4.9 ± 8.3 PD, 4.6 ± 9.5 PD, and 5.5 ± 10.3 PD, whereas those in the botulinum toxin group were 51.2 ± 14.3 PD, 13.9 ± 17.4 PD, 22.0 ± 19.3, and 31.3 ± 23.8 PD, respectively. There was a statistically significant difference in the deviation angles between the two groups ( p < 0.001). The success rate in the surgery group at one, three, and six months was 81%, 84%, and 79%, whereas that in the botulinum toxin group was 50%, 27%, and 27%. Conclusion: Botulinum toxin injection was not as effective as conventional extraocular muscle surgery in AACE patients. However, the treatment is safe, fast-acting, and improves both cosmetic appearance and quality of life. This may be considered as a chance for patients not preferring surgery. Keywords: botulinum toxin, muscle surgery, acute acquired comitant esotropia Esotropia is a common type of strabismus that mostly occurs after infancy or during childhood, but it could appear in adults or even the elderly. 1,2 Acute acquired comitant esotropia (AACE) is a subtype of esotropia defined by acute onset, the same deviation angle in all directions of gaze, and normal ocular motility. 3 AACE can have various causes such as visual deprivation, refractive error, neurological abnormality, and excessive near work. 3–5 The incidence of AACE appears to have risen in recent years, which may be attributable to increased computer and smartphone use. Moreover, the COVID-19 pandemic has led to more people working and studying online, which may aggravate the condition. 6,7 AACE may reduce the quality of life, causing diplopia, impaired stereopsis, and/or cosmetic, social, and amblyopic problems, the latter of which may lead to poor vision and blindness in children. Currently, choices for treatment include horizontal rectus muscle surgery 2,8 and botulinum toxin injection. 9,11 Due to the increasing number of AACE patients and insufficient hospital resources, the waiting list for surgery can be extremely long. In such cases, botulinum toxin may be employed as an alternative treatment. However, its rate of success remains unclear, as does the duration of its effect. Previous studies have reported botulinum toxin injection as being as effective as conventional rectus muscle surgery. 4,9,13 However, the samples in those studies were too small to draw a definitive conclusion. Based on our personal clinical experience, we hypothesize that botulinum toxin may not be as effective as strabismus surgery and the magnitude of deviation may alter the result of treatment. The aim of this study was, therefore, to compare the success rate of strabismus surgery with that of botulinum toxin injection and compare the results in different magnitude of deviation angle in a larger series of AACE patients. This retrospective cohort study was conducted in accordance with the Declaration of Helsinki and was approved by the Khon Kaen University Ethics Committee for Human Research (HE641629). Medical records of AACE patients who had been treated either by rectus muscle surgery or botulinum toxin injection at the KKU Eye Center, Srinagarind Hospital, Khon Kaen University, Thailand, from January 2014 to October 2021 were comprehensively reviewed. Although patient consent to review their medical records was not required by the ethics committee, the data in case report forms nevertheless had no linkage to the patient identities and the patient data confidentiality was protected. Diagnostic criteria of AACE consisted of acute onset, the same deviation angle in all directions of gaze, and normal ocular motility. Inclusion criteria were patients who met these diagnostic -Abstract Truncated-
[Preoperative prediction of the amount of surgical correction by using Botulinum A type toxin for the treatment of paralytic esotropia]

H Iwashige,H Takahashi,K Nakamura,Y Nemoto,T Ishida,T Maruo

Abstract:The aim of this study was to obtain the correct choice of initial surgical procedure and to predict the amount of surgical correction by using the maximum reduction rate of eye position after Botulinum A-type toxin injection for the treatment of acquired neurogenic paralytic strabismus. The subjects were 30 with sixth nerve palsy and 33 with non-paralytic esotopia with no previous surgery. The results were that if the maximum reduction rate of eye position after the first injection of 1.25 U was less than 68%, the modified Jensen procedure with recession of medial rectus muscle was necessary to achieve 100% recovery. However, if it was more than 100%, then recession-resection of the horizontal rectus muscles alone produced successful ocular alignment. Based on our data of 100 cases of sixth nerve palsy that showed spontaneous recovery, we conclude that surgical treatment should be planned, if the maximum percentage reduction of preoperative eye position after Botulinum A-type toxin treatment is under 68% (reflecting the inability of the medial rectus muscle to contract and the lengthening of the lateral rectus muscle), and if the patient has no spontaneous improvement at all within 12 weeks after onset.

Our data are good enough.

Botulinum toxin A for the treatment of strabismus in children with neurological impairment

Botulinum toxin for the treatment of strabismus

Factors Affecting the Efficacy of Botulinum Toxin Injection in the Treatment of Infantile and Partially Accommodative Esotropia

Comparison of the Efficiency of the Botulinum Toxin for the Treatment of Esotropia in Children with and without Neurological Disease and/or Prematurity

Comparison of Botulinum Toxin With Surgery for the Treatment of Acute-Onset Comitant Esotropia in Children

A Comparative Analysis of Surgical Outcomes for Infantile Esotropia With and Without Prior Botulinum Toxin a Injection

The role of botulinum toxin in decompensated strabismus

Efficacy of Botulinum Toxin Injection in Exotropia Treatment

Long-Term Effects of Botulinum Toxin A for Horizontal Concomitant Strabismus in Chinese Children

Binocular Visual Rehabilitation in Paralytic Strabismus by Botulinum A Toxin Chemodenervation

Relation between serum magnesium level and migraine attacks.

Comparison of botulinum toxin with surgery as primary treatment for infantile esotropia

Botulinum toxin management of childhood intermittent exotropia

Structure-release rate correlation in collagen gels containing fluorescent drug analog.

Botulinum Toxin in the treatment of strabismus. A review of its use and effects

Exploration of Effect and Dosage of Botulinum Toxin Type A for Long-Term Treatment of Idiopathic Blepharospasm

Long-term results of botulinum toxin in consecutive and secondary exotropia: outcome in patients initially treated with botulinum toxin

Evaluation of the efficacy of botulinum toxin injection for the treatment of infantile esotropia

Botulinum Toxin Injection versus Extraocular Muscle Surgery for Acute Acquired Comitant Esotropia

[Preoperative prediction of the amount of surgical correction by using Botulinum A type toxin for the treatment of paralytic esotropia]